FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120806423> ?p ?o ?g. }

• W2120806423 endingPage "350" @default.
• W2120806423 startingPage "342" @default.
• W2120806423 abstract "Rationale: Recent studies of inhaled tobramycin in subjects with cystic fibrosis (CF) find less clinical improvement than previously observed. Nonhuman data suggest that in some strains of Pseudomonas aeruginosa, azithromycin can antagonize tobramycin.Objectives: We tested the hypothesis that concomitant azithromycin use correlates with less improvement in key outcome measures in subjects receiving inhaled tobramycin while not affecting those receiving a comparative, nonaminoglycoside inhaled antibiotic.Methods: We studied a cohort of 263 subjects with CF enrolled in a recent clinical trial comparing inhaled tobramycin with aztreonam lysine. We performed a secondary analysis to examine key clinical and microbiologic outcomes based on concomitant, chronic azithromycin use at enrollment.Measurements and Main Results: The cohort randomized to inhaled tobramycin and reporting azithromycin use showed a significant decrease in the percent predicted FEV1 after one and three courses of inhaled tobramycin when compared with those not reporting azithromycin use (28 d: −0.51 vs. 3.43%, P < 0.01; 140 d: −1.87 vs. 6.07%, P < 0.01). Combined azithromycin and inhaled tobramycin use was also associated with earlier need for additional antibiotics, lesser improvement in disease-related quality of life, and a trend toward less reduction in sputum P. aeruginosa density. Subjects randomized to inhaled aztreonam lysine had significantly greater improvement in these outcome measures, which were unaffected by concomitant azithromycin use. Outcomes in those not using azithromycin who received inhaled tobramycin were not significantly different from subjects receiving aztreonam lysine. Azithromycin also antagonized tobramycin but not aztreonam lysine in 40% of P. aeruginosa clinical isolates tested in vitro.Conclusions: Oral azithromycin may antagonize the therapeutic benefits of inhaled tobramycin in subjects with CF with P. aeruginosa airway infection." @default.
• W2120806423 created "2016-06-24" @default.
• W2120806423 creator A5007307330 @default.
• W2120806423 creator A5010924080 @default.
• W2120806423 creator A5012122740 @default.
• W2120806423 creator A5014707042 @default.
• W2120806423 creator A5015765237 @default.
• W2120806423 creator A5022753869 @default.
• W2120806423 creator A5029360375 @default.
• W2120806423 creator A5036551975 @default.
• W2120806423 creator A5054931656 @default.
• W2120806423 date "2014-03-01" @default.
• W2120806423 modified "2023-10-01" @default.
• W2120806423 title "Azithromycin May Antagonize Inhaled Tobramycin When Targeting <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis" @default.
• W2120806423 cites W1521667132 @default.
• W2120806423 cites W1557639454 @default.
• W2120806423 cites W1600041372 @default.
• W2120806423 cites W1886252892 @default.
• W2120806423 cites W1974169283 @default.
• W2120806423 cites W1980472079 @default.
• W2120806423 cites W1996215008 @default.
• W2120806423 cites W1997392516 @default.
• W2120806423 cites W2008640098 @default.
• W2120806423 cites W2020366537 @default.
• W2120806423 cites W2038257815 @default.
• W2120806423 cites W2043577823 @default.
• W2120806423 cites W2046513922 @default.
• W2120806423 cites W2047758711 @default.
• W2120806423 cites W2069975147 @default.
• W2120806423 cites W2070458418 @default.
• W2120806423 cites W2075069205 @default.
• W2120806423 cites W2078078890 @default.
• W2120806423 cites W2085575233 @default.
• W2120806423 cites W2088190606 @default.
• W2120806423 cites W2090648579 @default.
• W2120806423 cites W2097200950 @default.
• W2120806423 cites W2101223241 @default.
• W2120806423 cites W2103227563 @default.
• W2120806423 cites W2103884572 @default.
• W2120806423 cites W2109451544 @default.
• W2120806423 cites W2111698236 @default.
• W2120806423 cites W2124135806 @default.
• W2120806423 cites W2132861283 @default.
• W2120806423 cites W2139861245 @default.
• W2120806423 cites W2140849505 @default.
• W2120806423 cites W2149512006 @default.
• W2120806423 cites W2149953588 @default.
• W2120806423 cites W2162335168 @default.
• W2120806423 cites W2168849280 @default.
• W2120806423 cites W2317332612 @default.
• W2120806423 cites W2320869932 @default.
• W2120806423 cites W4232966707 @default.
• W2120806423 cites W90700505 @default.
• W2120806423 doi "https://doi.org/10.1513/annalsats.201310-352oc" @default.
• W2120806423 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4028742" @default.
• W2120806423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24476418" @default.
• W2120806423 hasPublicationYear "2014" @default.
• W2120806423 type Work @default.
• W2120806423 sameAs 2120806423 @default.
• W2120806423 citedByCount "65" @default.
• W2120806423 countsByYear W21208064232014 @default.
• W2120806423 countsByYear W21208064232015 @default.
• W2120806423 countsByYear W21208064232016 @default.
• W2120806423 countsByYear W21208064232017 @default.
• W2120806423 countsByYear W21208064232018 @default.
• W2120806423 countsByYear W21208064232019 @default.
• W2120806423 countsByYear W21208064232020 @default.
• W2120806423 countsByYear W21208064232021 @default.
• W2120806423 countsByYear W21208064232022 @default.
• W2120806423 crossrefType "journal-article" @default.
• W2120806423 hasAuthorship W2120806423A5007307330 @default.
• W2120806423 hasAuthorship W2120806423A5010924080 @default.
• W2120806423 hasAuthorship W2120806423A5012122740 @default.
• W2120806423 hasAuthorship W2120806423A5014707042 @default.
• W2120806423 hasAuthorship W2120806423A5015765237 @default.
• W2120806423 hasAuthorship W2120806423A5022753869 @default.
• W2120806423 hasAuthorship W2120806423A5029360375 @default.
• W2120806423 hasAuthorship W2120806423A5036551975 @default.
• W2120806423 hasAuthorship W2120806423A5054931656 @default.
• W2120806423 hasBestOaLocation W21208064232 @default.
• W2120806423 hasConcept C126322002 @default.
• W2120806423 hasConcept C2775832221 @default.
• W2120806423 hasConcept C2776938444 @default.
• W2120806423 hasConcept C2777637488 @default.
• W2120806423 hasConcept C2778907293 @default.
• W2120806423 hasConcept C2778974779 @default.
• W2120806423 hasConcept C2779384505 @default.
• W2120806423 hasConcept C2779631663 @default.
• W2120806423 hasConcept C2780416669 @default.
• W2120806423 hasConcept C501593827 @default.
• W2120806423 hasConcept C523546767 @default.
• W2120806423 hasConcept C54355233 @default.
• W2120806423 hasConcept C71924100 @default.
• W2120806423 hasConcept C86803240 @default.
• W2120806423 hasConcept C89423630 @default.
• W2120806423 hasConcept C94665300 @default.
• W2120806423 hasConcept C98274493 @default.
• W2120806423 hasConceptScore W2120806423C126322002 @default.

• next